IDYA News and Press, IDEAYA Biosciences Inc. From 04/19/23

IDEAYA Announces First Patient Dosed in Phase 1 Clinical Trial for IDE161 as Potential First-in-Class PARG Inhibitor Targeting HRD Solid Tumors PR Newswire - Evaluating IDE161 in patients having solid tumors with HRD, with expansion focus in ER+ / Her2- breast cancer with HRD, r...

IDEAYA Biosciences to Participate in Upcoming April 2023 Investor Relations Event PR Newswire SOUTH SAN FRANCISCO, Calif. , April 3, 2023 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and...

IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) PR Newswire SOUTH SAN FRANCISCO, Calif. , March 31, 2023 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery ...

2023-03-24 16:24:16 ET Summary IDEAYA Biosciences, Inc.'s platform is synthetic lethality targeting cancer. The company has produced solid proof of concept data from multiple programs. Cash is strong, and big pharma is interested in IDEAYA Biosciences, Inc. and its work. ...

2023-03-07 06:17:50 ET IDEAYA Biosciences press release ( NASDAQ: IDYA ): Q4 GAAP EPS of -$0.50 beats by $0.06 . Revenue of $4.02M (+35.8% Y/Y) misses by $2.98M . For further details see: IDEAYA Biosciences GAAP EPS of -$0.50 beats by $0.06, revenue of $4...

IDEAYA Biosciences, Inc. Reports 2022 Financial Results and Provides Business Update PR Newswire Strong balance sheet of ~$373.1 million cash, cash equivalents and marketable securities as of December 31, 2022 is anticipated to fund planned operations into 2026 Pla...

IDEAYA Biosciences to Participate in Investor Conferences in March 2023 PR Newswire SOUTH SAN FRANCISCO, Calif. , March 1, 2023 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a synthetic lethality focused precision medicine oncology company committ...

IDEAYA Biosciences to Participate in Citi's 2023 Virtual Oncology Leadership Summit PR Newswire SOUTH SAN FRANCISCO, Calif. , Feb. 16, 2023 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a synthetic lethality focused precision medicine oncology company ...

IDEAYA Biosciences to Participate in the 2023 Guggenheim Oncology Conference PR Newswire SOUTH SAN FRANCISCO, Calif. , Feb. 1, 2023 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a synthetic lethality focused precision medicine oncology company com...

Ideaya Biosciences ( NASDAQ: IDYA ) said it started enrollment in a phase 2 trial of darovasertib as monotherapy in neo-adjuvant and adjuvant settings in patients with primary, non-metastatic uveal melanoma (UM). UM is a type of eye cancer. In one group patients with large tu...